Overview

Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation

Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
A randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation
Phase:
Phase 4
Details
Lead Sponsor:
HaEmek Medical Center, Israel
Treatments:
Medroxyprogesterone
Medroxyprogesterone Acetate